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Abstract
Dietary supplementation with natural chemoprotective agents is receiving considerable attention because of health
benefits and lack of toxicity. In recent in vivo and in vitro experimental studies, diets rich in n-3 polyunsaturated fatty acids
have been shown to provide significant anti-tumor action. In this investigation, the effects of control fatty acids (oleic acid
(OA), linoleic acid (LA)) and n-3 PUFA, e.g., docosahexaenoic acid (DHA) on the uptake and metabolism of the carcinogenic
polycyclic aromatic hydrocarbon, benzo[a]pyrene (BaP) was investigated in A549 cells, a human adenocarcinoma alveolar
basal epithelial cell line. A549 cells activate BaP through the cytochrome P450 enzyme system to form reactive metabolites,
a few of which covalently bind to DNA and proteins. Therefore, multiphoton microscopy spectral analysis combined with
linear unmixing was used to identify the parent compound and BaP metabolites formed in cells, in the presence and
absence of fatty acids. The relative abundance of select metabolites was associated with altered P450 activity as determined
using ethoxyresorufin-O-deethylase activity in cells cultured in the presence of BSA-conjugated fatty acids. In addition, the
parent compound within cellular membranes increases significantly in the presence of each of the fatty acids, with the
greatest accumulation observed following DHA treatment. DHA treated cells exhibit significantly lower pyrene-like
metabolites indicative of lower adducts including DNA adducts compared to control BSA, OA or LA treated cells. Further,
DHA reduced the abundance of the proximate carcinogen BaP 7,8-dihydrodiol and the 3-hydroxybenzo[a]pyene
metabolites compared to other treatments. The significant changes in BaP metabolites in DHA treated cells may be
mediated by the effects on the physicochemical properties of the membrane known to affect enzyme activity related to
phase I and phase II metabolism. In summary, DHA is a highly bioactive chemo-protective agent capable of modulating BaP-
induced DNA adducts.
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Introduction
Exposure to polycyclic aromatic hydrocarbons (PAHs) usually
occurs by breathing contaminated air or by eating grilled foods.
Several PAHs have been listed by the U.S. Environmental
Protection Agency as probable human carcinogens and this
includes the prototype carcinogenic PAH, benzo[a]pyrene (BaP)
[1]. As a ligand for the aryl hydrocarbon receptor (AhR), BaP
upregulates the expression of phase I bioactivation genes and
phase II conjugation genes [2,3]. Induction of biotransformation
enzymes including CYP1A1, CYP1B1 and epoxide hydrolase
metabolically activate BaP to different types of metabolites
including hydroxylated intermediates, epoxides, quinones, dihy-
drodiols, dihydrodiol epoxides and various metabolite-conjugates
in cells [4,5]. BaP toxicity results from the bioactivation of BaP to
the ultimate toxic compound, benzo[a]pyrene-7,8-dihydrodiol-
9,10-epoxide (BPDE). BPDE can alkylate DNA to form BPDE-
DNA adducts (BPDE-N(2)-deoxyguanosine [BPDE-dG]), which
have been associated with BaP-induced carcinogenesis [6]. In
addition, many of the major metabolites can be conjugated to
glucuronic acid, sulfate and glutathione to become more water
soluble facilitating excretion [7].
Studies over the last four decades have shown that diet can
modulate the response of organisms to drug absorption, distribu-
tion, metabolism, and excretion [8,9]. Diet is also known to
modulate carcinogenesis; for example, n-3 fatty acids, especially
the long-chain polyunsaturated fatty acids (PUFAs), eicosapentae-
noic acid (EPA) and docosahexaenoic acid (DHA) present in fatty
fish and fish oils inhibit carcinogenesis [10,11]. Furthermore,
dietary fish oil has recently been shown to play a protective role in
PAH- (including BaP-) induced hepatic carcinogenesis and to
significantly reduce levels of DNA adducts in mice, leading to
further reinforcement of the idea that fish oil can be used as a
cancer chemopreventative agent [12].
In a previous work, we demonstrated that with the use of the
multiphoton microscopy imaging at an excitation of 740 nm and
the mathematical unmixing process, it is possible to simultaneously
identify 8 of the major metabolites of BaP in real time in live
cultured cells. This technique proved useful to quantify specific
metabolites in [13].
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Therefore, the aims of this study were: (1) to investigate the role
of some dietary fatty acids (polyunsaturated fatty acids: n-3 PUFAs
(DHA), n-6 PUFA linoleic acid (LA), n-9 monounsaturated fatty
acid [n-MUFA] or oleic acid [(OA])) in BaP metabolic activation
and metabolism in A549 lung adenocarcinoma cells using the
spectral unmixing approach and (2) to elucidate how these dietary
factors may provide increased or decreased protection against
BaP-induced adduct formation.
Materials and Methods
Materials
Dulbecco’s Modified Eagle’s Medium/Ham’s Nutrient Mixture
F-12 (DMEM-F12), fatty acid free bovine serum albumin (BSA),
Dulbecco’s phosphate buffered saline (PBS), glutathione (GSH),
benzo[a]pyrene (BaP), L- buthionine sulfoximine (BSO), janus
green, b-glucuronidase (keyhole limpet, #G8132), triclosan
(Irgasan), resorufin, ethyl ether, 3,39-methylene-bis(4-hydroxycou-
marin) (dicumarol), and trans-3,49,-5-trihydroxystilebene; 3,49,5-
stilbenetriol (resveratrol) were purchased from Sigma-Aldrich
Chemical Co. (St. Louis, MO). Fetal bovine serum (FBS) was
obtained from Equitech-Bio (Kerrville, TX). 3-Hydroxybenzo[a]-
pyrene (3OH), 9-Hydroxybenzo[a]pyrene (9OH), benzo(a)pyrene-
trans-7, 8- dihydrodiol(+/2) (t7,8), benzo[a]pyrene-r-7,t-8-dihy-
drodiol-t-9,10-epoxide(6),(anti) (BPDE), pyrene (Pyr), benzo(a)py-
rene-3-sulfate (3-S), and benzo[a]pyrene-3,6-dione (3,6BPQ), were
purchased from Midwest Research Institute (Kansas City, MO)
which operates the Chemical Carcinogen Reference Standard
Repository. Analytical data provided with each standard was
reported as .99% pure by HPLC and UV/visible spectra. These
UV/visible spectra were also confirmed prior to use in cells. Tissue
culture flasks, 2-well Lab-Tek chambered coverglass slides were
purchased from Thermo Fisher Scientific (Waltham, MA) and
multi well plates were purchased from Corning Inc. (Corning,
NY). The XIT Genomic DNA kit was purchased from G-
Biosciences (St. Louis, MO). The OxiSelect BPDE DNA Adduct
ELISA Kit was purchased from Cell Biolabs Inc. (San Diego, CA).
Fatty acids (oleic acid (OA), linoleic acid (LA) and docosahex-
aenoic acid (DHA)) were purchased from NuChek (Elysian, MN)
and were complexed with BSA to form aqueous-soluble reagent
that can be absorbed and utilized by cells [14]. BaP, 3OH, t7,8
were each prepared as 1 mM stocks in DMSO. Resorufin ethyl
ether was prepared as a 1 mM stock in methanol and diluted to
4 mM for EROD activity measurement. Janus green was prepared
in PBS at 1 mg/ml. Both GSH and BSO were prepared as
10 mM stock in DMEM-F12.
Alpha-naphtoflavone (aNF) was purchased from Fisher Scien-
tific (Pittsburg, PA) and prepared as 100 mM stock in DMSO.
Monochlorobimane was purchased from Life Technologies
(Grand island, NY) and pepaed as 50 mM stock in DMSO.
Cell Culture
The A549 cell line, derived from type II pneumocytes (CCL
185) was obtained from American Type Culture Collection
(Manassas, VA). A549 cells express phase I and II enzymes
involved in detoxification or bioactivation of pulmonary toxicants
and respond to P450 inducers, albeit at a lower level than normal
human type II pneumocytes [15]. Cells were cultured in DMEM-
F12 medium with 10% FBS. Cultures were approximately 80%
confluent at the time of analysis.
Ethoxyresorufin-O-deethylase (EROD) Activity
EROD activity is a biomarker of exposure to planar haloge-
nated and polycyclic aromatic hydrocarbons (PHHs and PAHs,
respectively) and provides evidence of aryl hydrocarbon receptor-
mediated induction of cytochrome P450-dependent monooxygen-
ases [16]. To quantify the induction of EROD activity following
BaP and/or fatty acid treatments, cells were plated on 96 well-
plates at 10,000/well for 24 h in the presence or absence of fatty
acids prior to treatment with 0.5 mM BaP or vehicle control for
another 48 h. Following two washes with PBS and three cycles of a
freeze/thaw process (280uC for 5 min), plates were then loaded
with a mixture of 4 mM resorufin ethyl ether, 10 mM dicumarol
and 0.5 mM NADPH for 30 min. EROD activity was measured
using a BioTek Synergy 4 plate reader (Biotek Instruments Inc.,
Winooski, VT, USA) with an excitation wavelength of 560 nm
and an emission wavelength of 590 nm. Cell number per well was
determined using the Janus green assay (as described below) and
EROD fluorescence intensities measured were normalized ac-
cordingly. Fifteen samples per treatment were collected and at
least 3 experiments were performed on different days.
Cell Count/Janus Green Assay
Following the EROD assay, Janus green (1 mg/ml) was added
to each well and incubated at room temperature for 5 min. Cells
were again washed twice with PBS and 100 ml of methanol was
added to each well. Janus green signal was then measured using a
BioTek Synergy 4 plate reader set to an absorbance of 630 nm.
Multiphoton Spectral Analysis of BaP in A549 Cells
A549 cells were cultured for 48 h in DMEM F-12 with 10%
FBS and 50 mM of each of the BSA-conjugated fatty acids (OA,
LA or DHA) or BSA control on 2-well Lab-Tek slides at a density
of 105 cells per well. The dose of 50 mM of the fatty acids has been
shown to alter cell signaling [17] and to induce no cytotoxicity in
normal cells [18,19]. Cells were then incubated for an additional
24 h with 2 mM BaP. Treatments were then removed by washing
cells with serum- and phenol red-free culture medium and slides
were transferred to the stage of a Zeiss 510 META NLO laser
scanning microscope (Carl Zeiss Microimaging, Thornwood, NY).
Spectral analysis of an area of 2256225 mm (typically containing
25 to 40 cells) was performed while irradiating cells with a
Chameleon tunable Ti:Sapphire laser (Coherent Inc., Santa Clara,
CA) at an excitation wavelength of 740 nm (which is roughly
equivalent to 370 nm in single photon excitation with a
continuous wavelength laser system). Using the lambda stack
algorithm software available with the Zeiss 510 META NLO
instrument, a fluorescence emission spectrum ranging from 399–
600 nm with a 10.7 nm bandwidth was recorded for each scanned
area. Thirty areas were scanned per treatment. All images were
collected with a C-Apo 406/1.2 NA water immersion objective
designed for viewing specimens in an aqueous medium. BaP
metabolites present in each treatment were then identified using
the linear unmixing process based upon the use of a spectral
database of BaP and metabolite standards generated under the
same experimental conditions as previously described [13].
Deciphering the Effects of Fatty Acids on BaP metabolism
To further determine the effects of each fatty acid on BaP
metabolites generated in A549 cells, triclosan was used as a
substrate and inhibitor of glucuronidation and sulfation [20]. In
addition, b-glucuronidase was used as a catalyst for the hydrolysis
of the water-soluble glucuronide conjugates of BaP generated in
phase II detoxification reactions which is capable of increasing the
hydroxyl metabolites of BaP [21]. To conduct the triclosan
experiments, A549 cells were plated on coverglass slides and
directly supplemented for 48 h with the fatty acid (OA, LA, or
DHA) or BSA control followed by treatment with 2 mM BaP or
Fatty Acids Alter Metabolism in Lung Cancer Cells
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the combination of 2 mM BaP and 40 mM triclosan for 24 h. Cells
were then washed, scanned under the same experimental
conditions and the t7,8 metabolites were evaluated. For b-
glucuronidase experiments, cells were supplemented for 48 h with
BSA-conjugated fatty acids (OA, LA or DHA) or BSA control
followed by treatment with 1 mM 3OH, or a combination of 1 mM
3OH and 500 units/ml b-glucuronidase, 2 mM t7,8 or a
combination of 2 mM t7,8 and 500 units/ml b-glucuronidase for
24 h. Cells were then washed, scanned on the stage of the
multiphoton microscope and the 3OH and t7,8 metabolites were
evaluated.
To further investigate the role of fatty acids in the metabolism of
BaP through glutathionation, L-buthionine sulfoximine (BSO
1 mM-10 mM), a potent and specific inhibitor of glutathione
(GSH) synthesis via c-glutamyl synthase [22] and supplementation
of cells with GSH were used. To determine the changes in
metabolites generated by BaP due to treatments with BSO or
GSH, cells were plated on coverglass slides in the presence of the
BSA-conjugated fatty acids (OA, LA or DHA) or BSA control for
48 h followed by 2 mM BaP, 2 mM BaP and 1 mM BSO, or 2 mM
BaP and 10 mM GSH for another 24 h. Cells were then washed
and scanned on the stage of the multiphoton microscope and the
3OH, t7,8 and Pyr metabolites were evaluated.
To determine the changes in metabolites generated by 3OH
due to treatments with BSO or GSH, cells were plated on
coverglass slides in the presence of the BSA-conjugated fatty acids
(OA, LA or DHA) or BSA control for 48 h followed by 1 mM
3OH, 1 mM 3OH and 1 mM BSO, or 1 mM 3OH and 10 mM
GSH for another 24 h. Cells were then washed and scanned on
the stage of the multiphoton microscope and the 3OH metabolites
were evaluated.
BPDE-DNA Adduct Measurements
DNA was isolated using the XIT Genomic DNA kit according
to the manufacturer instructions. The spectrum of BPDE-DNA
was identified from the BPDE-DNA standard provided in the
OxiSelectTM BPDE DNA Adduct ELISA Kit. The BPDE-DNA
signal was then determined with a Biotek Synergy plate reader
using lysates of cells that were supplemented with 50 mM BSA-
conjugated fatty acids (OA, LA or DHA) or BSA control for 48 h
followed by 24 h of treatment with 2 mM BaP.
Statistical Analysis
Measurements of EROD activity are presented as mean
normalized fluorescence intensities 6 S.E. of 15 samples per
concentration and measurements of BPDE-DNA adducts are
presented as means 6 S.E. with 3 samples per treatment. Data
collected by multiphoton microscopy are reported as mean
fluorescence intensities 6 S.E or normalized to the corresponding
control of at least 30 images per treatment. All data were analyzed
using two-sided t-tests for 2 samples comparison, One way-
ANOVA followed by Tukey’s test at P,0.05 for multiple
treatment comparison, and two way ANOVA followed by
Bonferroni’s test at p,0.05 for combined time and treatment
comparisons.
Results
Single Cell Multiphoton Spectral Analysis of BaP
A549 cells have been shown to have the capability to activate
BaP through the cytochrome P450 enzyme system (Figure A in
File S1) and to form reactive metabolites that covalently bind
nucleophilic sites of cellular macromolecules such as DNA [23,24].
Many of the BaP metabolites and their time-dependent changes in
liver cells have been detected in living cells using multiphoton
microscopy with the linear unmixing process [13]. Similar time-
dependent changes in BaP levels and metabolites in A549 cells are
shown in Figure 1. The parent compound and hydroxyl
metabolites (3OH and 9OH) decreased significantly while the
other reactive metabolites (t7,8, BPDE, Pyr and 3,6BPQ)
increased significantly 24 h following removal of BaP. In addition,
the AhR antagonist, a-naphtoflavone [25,26] added simultaneous-
ly with BaP significantly reduced the Pyr and 3S metabolites
(Figure B in File S1) while simultaneous treatment with BaP and
resveratrol (another competitive antagonist of AhR ligands) [27]
significantly reduced the parent compound BaP as well as the
9OH and Pyr metabolites (Figure C in File S1).
The relative abundance of several major metabolites changed
when cells were cultured in the presence of BSA-conjugated fatty
acids (OA, LA or DHA, each at 50 mM along with BSA as carrier
control) for 24 h in advance of 2 mM BaP exposure for 24 h
(Figure 2). Accumulation of the parent compound (BaP) within
cellular membranes increased significantly in the presence of each
of the three fatty acids (OA, LA, and DHA) when compared to
control, with the greatest accumulation observed in DHA treated
cells (Figure 3A). The 3OH and t7,8 metabolites were
significantly lower only in DHA-treated A549 cells (Figures 3B
and 3C). Furthermore, Pyr-like metabolites, thought to result
from BPDE-adduct formation, decreased with each of fatty acids
in the following order: DHA,LA=OA,BSA (Figure 3D). The
significant changes in BaP metabolites (t7,8 and Pyr) obtained with
DHA treatment persisted 24 h after removal of BaP and DHA
(Figure 4). It is also noteworthy that the uptake of BaP up to 1 h
is not significantly different between BSA and DHA treated cells
(Figure D in File S1).
To confirm that the decrease in the Pyr-like signal with fatty
acid treatments was due to reduced BPDE-DNA adducts, cells
were supplemented with 50 mMOA, LA, DHA or BSA carrier for
48 h prior to addition of 2 mM BaP for 24 h. The cellular content
of BPDE-DNA adducts was quantified. The emission of BPDE-
DNA as a function of fatty acid and BaP exposure indicate that LA
significantly decreased the BPDE-DNA adducts compared to BSA
carrier while DHA induced the greatest reduction in the BPDE-
DNA adducts (Figure 5).
Figure 1. BaP uptake and metabolism in A549 cells. Cells were
treated overnight with 2 mM BaP and metabolites were determined
directly and 24 h following removal of BaP. Note the reduction in
parent compound and the 3OH metabolite and the increase in 3,6,BPQ,
t7,8, BPDE and pyrene-like metabolites (Pyr) 24 h after removal of BaP
from the cultured cells. *indicates significant difference from the
corresponding control metabolite at p,0.05.
doi:10.1371/journal.pone.0090908.g001
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EROD Activity in BaP Treated A549 Cells
The effects of fatty acids on BaP activation of the cytochrome
P450 enzyme system was confirmed by assessment of EROD
activity in A549 cells supplemented with 50 mM BSA-conjugated
fatty acids (OA, LA, DHA, BSA-carrier control) for 48 h followed
by 0.5 mM BaP for 24 h (Figure 6). Cells treated with BSA+BaP
exhibited a significant increase in EROD activity compared to
basal EROD activity (BSA alone). OA alone did not significantly
affect the basal EROD activity and the combination treatment of
OA and BaP showed a similar EROD response to that of
BSA+BaP. Both LA and DHA significantly enhanced EROD
activity in the absence of BaP and further increased EROD
activity in the presence of BaP, with DHA responses in the absence
or presence of BaP significantly greater than LA.
Fatty Acid Effects on Glutathionation in BaP Treated
A549 Cells
To investigate the role of fatty acids in the metabolism of BaP
through glutathionation, L-buthionine sulfoximine and supple-
mentation of cells with GSH were used. A549 cells supplemented
with 50 mM BSA for 48 h followed by treatment with 2 mM BaP
and 1 mM BSO (BSA+BSO+BaP) resulted in a significant
increase in 3OH compared to BSA+BaP; and substitution of
BSO by 10 mM GSH (BSA+GSH+BaP) resulted in a significant
decrease in 3OH compared to BSA+BaP, presumably due to
formation of glutathione conjugates [7]. BSO treatment induced
similar results in LA treated cells while GSH had no significant
effect (Figure 7A). DHA treatment alone reduced 3OH
metabolites but addition of BSO or GSH to DHA did not cause
any additional effects (Figure 7A). In addition, BSO or GSH did
not alter t7,8 metabolites in any of the three treatments (BSA, LA
or DHA) (Figure 7B). In addition, supplementation of cells with
10 mM GSH reduced the Pyr-like metabolites in BSA, LA and
DHA treated cells (Figure 7C).
Figure 2. Pseudocolor images of BaP metabolites obtained
with A549 cells supplemented with fatty acids. Cells were
supplemented with each fatty acid: 50 mM BSA carrier control (top left
panel), OA (top right panel), LA (bottom left panel), and DHA (bottom
right panel). for 48 h prior to addition of 2 mM BaP for 24 h. Each image
represents the overlay of 7 metabolites represented by referenced
colors (BaP, 3OH, 9OH, t7,8, 3,6BPQ, BPDE and Pyr).
doi:10.1371/journal.pone.0090908.g002
Figure 3. Significant BaP metabolites in A549 cells supplemented with fatty acids. BaP (A), 3OH (B), t7,8 (C) and Pyr (D) profiles in cells.
A549 cells were incubated with BSA (carrier control), OA, LA or DHA for 48 h prior to addition of 2 mM BaP for 24 h. Data represent mean 6 SEM of
fluorescence intensity of significant metabolites: A) BaP, B) 3OH, C) t7,8, and D) Pyr measured in at least 30 images per treatment with at least 30 cells
per image. Letters above the bars represent significant differences within a treatment for each evaluated metabolite using Tukey test at p,0.05. No
significant differences were found in the other metabolites measured (9OH, BPDE or 3,BPQ).
doi:10.1371/journal.pone.0090908.g003
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Since DHA treated cells did not show any major changes in BaP
metabolites (3OH, t7,8 and Pyr) with GSH or BSO, we evaluated
the activity of the glutathionation pathway using a 3OH standard
directly as a treatment instead of BaP. BSO significantly increased
the 3OH metabolites in all three treatments with the largest
increase induced by DHA treated cells (Figure 8). This indicates
that the gluathionation pathway is highly active in DHA treated
cells. This is also verified by measuring the GST activity using
monochlorobimane (Figure E in File S1) [28]. The fact that no
significant results were seen with BSO and BaP in DHA treated
cells (Figure 8) could indicate the activation of other pathways
(such as glucuronidation or sulfation).
Fatty Acid Effects on Glucuronidation and Sulfation of
BaP Metabolites
To investigate the role of fatty acids in the metabolism of BaP
through glucuronidation, A549 cells were supplemented with the
fatty acids (BSA, LA or DHA) for 48 h followed by BaP and 500
units of b-glucuronidase for 24 h. b-glucuronidase resulted in a
modest but significant increase in the free 3OH metabolite of BaP
in BSA compared to cells treated with BSA alone whereas LA and
DHA treated cells were unaffected by the presence of b-
glucuronidase (Figure 9A) indicating that 3OH-glucuronidation
is not induced in LA or DHA treated cells (Zhu li et al., 2008). In
comparison, with respect to glucuronidation of t7,8, no significant
glucuronidation was detected in any of the treatments tested (data
not shown).
t7,8 is a metabolic precursor of BPDE, the carcinogenic BaP
metabolite that alkylates DNA [6]. Formation of t7,8 is dependent
on metabolism of BaP into the 7,8 oxide which in turn is
hydrolyzed to t7,8. Since t7,8 was significantly reduced in DHA
treated cells, we investigated the effect of fatty acids on sulfate
conjugation of t7,8 in A549 cells supplemented with either BSA,
LA or DHA for 48 h followed by 2 mM BaP in the presence or
absence of triclosan (a competitive inhibitor of sulfation and to a
lesser extent glucuronidation) for another 24 h. Triclosan added to
cells supplemented with BSA did not show any increase in t7,8
Figure 4. Comparison of BaP metabolites (BaP, 3OH, t7,8 and Pyr) in BSA and DHA supplemented cells. Cells were supplemented with
BSA or DHA for 48 h prior to addition of 2 mM BaP for 24 h. Cells were then imaged directly 0 h (A) and 24 h (B) after removal of BaP. Note that the
decrease in t7,8 and Pyr metabolites in DHA treated cells are persistent even 24 h after removal of BaP. Data represent mean normalized intensity
(with respect to BSA 0 h) 6 SEM of at least 30 images per treatment with at least 30 cells per image. Letters above the bars represent significant
differences from the corresponding control for each evaluated metabolite using two-way ANOVA followed by Bonferroni test at p,0.05.
doi:10.1371/journal.pone.0090908.g004
Figure 5. BPDE-DNA adduct formation in A549 cells supple-
mented with fatty acids. Cells were incubated with 50 mM OA, LA,
DHA or BSA carrier for 48 h prior to addition of 2 mM BaP for 24 h.
Values represent results from a typical experiment with mean ratio
(BPDE-DNA/BPDE) 6 SEM of at least 3 replicates per treatment.
Different letter indicates significant difference using Tukey’s multiple
comparison test at p,0.05.
doi:10.1371/journal.pone.0090908.g005
Figure 6. EROD activity in A549 cells supplemented with BSA-
conjugated fatty acids (OA, LA, DHA, BSA). Cells were treated
with each of the fatty acids for 48 h followed by 0.5 mM BaP for 24 h.
Data represent mean 6 SEM of a typical experiment with 3 replicates
per treatment. * indicates significant difference between two compared
treatments using two-tailed t-test at p,0.05.
doi:10.1371/journal.pone.0090908.g006
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metabolite compared to BSA alone (Figure 9A). However,
triclosan added to cells supplemented with LA or DHA showed
a significant increase in t7,8 metabolite compared to the
corresponding control (LA alone or DHA alone), with the highest
level of t7,8 accumulation present in DHA treated cells
(Figure 9B).
Discussion
Metabolism of BaP is complex and involves biological activation
through oxidative metabolism by cytochrome p450s and other
enzymes responsible for Phase I reactions. The ultimate carcin-
ogen, BPDE, results from metabolic activation by cytochrome
P4501A1 and 1B1 enzymes and hydrolysis by epoxide hydrolase
[29]. Numerous additional metabolites are also generated
including epoxides, phenols, dihydrodiols, quinones, triols, tetrols
and diol epoxides [30,31] and these metabolic products can affect
a wide variety of cellular responses. Many of these metabolites can
be conjugated to glucuronic acid, sulfate and glutathione in Phase
II reactions to become more water soluble facilitating their
excretion [7] (Figure F in File S1). Real time analysis of the
parent compound and selected metabolites has been reported
using multiphoton laser scanning microscopy combined with the
advanced linear unmixing process in several cell types [13,32].
Results of the present study which simultaneously examines
seven major metabolites (BaP, 3OH, 9OH, t7,8, BPDE, Pyr, 3S
and 3,6BPQ) confirm that A549 cells treated with BaP activate
CYP1A1/CYP1B1 and produce more reactive intermediates that
form DNA adducts (Figure A in File S1 and Figure 1).
Supplementing A549 cultured lung cells with fatty acid altered the
metabolite distribution primarily through a decrease in 3OH, t7,8
and Pyr-like metabolites (Figure 3) with the greatest decrease
obtained with DHA supplementation; and this was maintained
24 h after removal of DHA (Figure 4). DHA supplementation
also decreased BPDE-DNA adduct formation (Figure 5). The
metabolism of BaP to t7,8 and BPDE is critical for the
carcinogenic effects of BaP [2]; and further metabolism of BPDE
to tetrols or adducts including DNA results in formation of pyrene
derivatives due to loss of aromatization of the D ring of BaP [13].
The observed decrease in BPDE-DNA adducts in cells supple-
mented with LA or DHA did not result from the decrease in
cytochrome P4501A1 and 1B1 enzymes and hydrolysis by epoxide
hydrolase since EROD activity was the highest in DHA
supplemented cells indicative of increased P450 activity
(Figure 6). This result is in agreement with the work of Zhou et
al. [12] who reported that fish oil rich in EPA and DHA reduces
the formation of DNA adducts in B6C3F1 male mice. This
decrease in DNA adducts was shown to be correlated with the
activation of the phase I enzyme Cyp1a1 and the phase II enzyme
Gstt1. Because CYP1A1 has been shown to be involved in both
detoxification and metabolic activation in a cell context dependent
manner [33–35], it is possible that in A549 cells, the increase in
EROD activity (increase in CYP1A1/CYP1B1) also contributed
significantly to the BaP detoxification. Other factors that
contributed to BaP detoxification with LA or DHA supplemen-
tation is the increase in sulfation of BaP metabolites in A549 cells.
This was verified using triclosan that itself undergoes sulfation and
glucuronidation and can be used as a competitive inhibitor of both
reactions [20]. In this study, the inhibitory effect of triclosan was
investigated as a function of the t7,8 metabolite formed in A549
cells treated with BaP and/or triclosan (Figure 9B). This
Figure 7. Glutathionation in A549 cells supplemented with BSA-conjugated fatty acids (LA, DHA, BSA carrier control). Cells were
treated with BSO or GSH in combination with each of the fatty acids for 48 h followed by 2 mM BaP for 24 h. Data represents mean normalized
intensity 6 SEM of at least 30 images per treatment and 30 cells per image. * indicates significant difference from the corresponding control using
Tukey test at p,0.05. Note that DHA treated cells did not show any significant changes in the metabolites (3OH, t7,8 and Pyr) in the presence of BSO
or GSH.
doi:10.1371/journal.pone.0090908.g007
Figure 8. Effect of BSO on the glutathionation of 3OH in A549
cells supplemented with fatty acids. Cells were treated with a fatty
acid (LA, DHA, BSA carrier control) and BSO for 48 h followed by 1 mM
3OH for 24 h. Data represents mean normalized intensity 6 SEM of at
least 30 images per treatment and 30 cells per image. * indicates
significant difference from the corresponding control using two-tailed t-
test at p,0.05. Note that all treatments accumulate equally the 3OH
and BSO decreased the GSH conjugates which induced higher
accumulation of 3OH. In addition, DHA and BSO combined induced
the greatest increase in 3OH.
doi:10.1371/journal.pone.0090908.g008
Figure 9. Assessment of BaP metabolites in A549 cells using
inhibitors of glucuronidation and sulfation. A) Measurement of
3OH metabolite in A549 cells supplemented with BSA-conjugated fatty
acids (LA, DHA, BSA carrier control) for 24 h followed by 2 mM BaP for
24 h in the presence or absence of 500 units of b-glucuronidase. B)
Measurement of t7,8 metabolite in A549 cells treated with BSA-
conjugated fatty acids (LA, DHA, BSA carrier control) for 24 h followed
by 2 mM BaP for 24 h in the presence or absence of 40 mM triclosan.
Data represents mean normalized intensity 6 SEM of at least 30 images
per treatment and 30 cells per image. * indicates significant difference
from the corresponding control using two-tailed t-test at p,0.05. Note
that glucuronidation (indicated by increase in 3OH due to the presence
of b-glucuronidase) is not significant in DHA or LA treated cells while
sulfation (indicated by increase in t7,8 due to the presence of triclosan)
is significantly enhanced in DHA and LA when compared to BSA.
doi:10.1371/journal.pone.0090908.g009
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experiment confirmed that sulfation is increased in LA and DHA
treated cells with the greatest increase induced with DHA.
However, no significant change in glucuronidation was observed
in LA or DHA supplemented cells (Figure 9A) when two
metabolites of BaP (3OH and t7,8) were measured. The selection
of these two metabolites was based on the fact that 3OH generates
the glucuronidated metabolite directly and t7,8 generates it
directly or indirectly. The absence of significant glucuronidation
of BaP metabolites (specifically 3OH and t7,8) may be due to the
fact that LA and DHA can also be competitively glucuronidated
[36] or to the activation of another phase II enzyme such as
glutathione S-transferase (Figure E in File S1) and therefore the
recruitment of other detoxification pathway such as the glutathi-
one pathway.
Glutathionation is important in DHA supplemented cells as
A549 cells supplemented with DHA or LA followed by BSO and
3OH exhibited an increase in 3OH accumulation indicative of a
decrease in glutathione conjugates (Figure 8). These data indicate
that DHA treated cells produce less hydroxyl metabolites of BaP
possibly due to activation of glutathione S-transferases (Figure E
in File S1), a class of phase II enzymes, that can detoxify PAHs
epoxides, quinones and hydroperoxides by conjugation with
glutathione, and/or due to a better export of phase II metabolites
in A549 cells [37]. This also may have contributed to the decrease
in BPDE-DNA adduct levels. However, when cells were treated
with BaP, glutathionation was significant only in control (BSA)
cells as determined by inhibition of glutathione-S-transferase
(BSO) or addition of GSH and examination of three BaP
metabolites (3OH, t7,8 and Pyr-like signals) (Figure 7). Therefore
other phase II conjugation pathways (such as sulfation) are active
(Figure 9B).
In addition to the above mentioned changes in BaP metabolites
in DHA or LA supplemented cells, a significant increase in the
membrane accumulation of the parent compound BaP was
observed. This is in agreement with other studies showing that
dietary or media lipid changes quickly alter the polyunsaturated
fatty acid composition of the membrane phospholipids [38–40]
and that changes in the fatty acid profiles of the membranes might
modify the physicochemical environment of the cell sufficiently to
affect such functions as receptor activity, enzyme activity or
permeability to chemical agents [41–46]. Therefore, the alter-
ations in cell membrane fatty acid composition induced by LA and
DHA appear to be factors underlying their differential actions on
BaP metabolism [47].
In summary, PUFA (LA and DHA) treatment increased BaP
membrane accumulation with the greatest increase induced in
DHA supplemented cells. This elevated membrane accumulation
in DHA was associated with the induction of phase I (P450) and II
(sulfotransferases, glutathione S-transfrases and UDP-glucurono-
sylransferases) metabolizing and detoxifying enzymes. The overall
outcome is the reduction of Pyr-like (adducts including DNA),
3OH and t7,8 metabolites (Figure 3) in DHA supplemented cells.
Further studies are needed to evaluate development of strategies
involving dietary supplement with DHA to reduce the risk of
human cancers caused by exposure to environmental PAHs.
Supporting Information
File S1 This file includes the following: Figure A. EROD
activity in A549 cells. Cells were treated with different
concentrations of BaP for 24 h. Data represent mean fluorescence
intensity of resorufin 6 SEM of a least 8 replicates per
concentration tested. Figure B. Effect of aNF on BaP
metabolites in A549 cells. Cells were cultured for 24 h in
the presence of BSA, treated simultaneously with 100 mM aNF
and 2 mM BaP for another 24 h before imaging. Note the
reduction in the Pyr and 3S metabolites in cells treated with aNF
compared to the corresponding metabolites generated by BaP.
*indicates significant difference from the corresponding control
metabolite at p,0.05. Figure C. Effect of resveratrol (R) on
BaP metabolites in A549 cells. Cells were cultured for 24 h in
the presence of BSA, treated simultaneously with 20 mM
resveratrol and 2 uM BaP for another 24 h before imaging. Note
the reduction in parent compound, 9OH and Pyr metabolites in
cells treated with resveratrol compared to the corresponding
metabolites generated by BaP. *indicates significant difference
from the corresponding control metabolite at p,0.05. Figure D.
Short term uptake of BaP in A549 cells. Note that BSA and
DHA treated cells accumulate BaP equally following 1 h exposure.
Data represents mean fluorescence intensity 6 S.E. of a least 15
images per treatment. Figure E. GST activity in A549 cells
following fatty acids and/or BaP treatments. A549 cells
treated with DHA alone exhibited a slight but significant increase
in GST activity when compared to cells treated with BSA alone
(A). Cells treated with DHA followed by BaP for 24 h exhibited
even a higher increase in GST activity when compared to BSA
followed by BaP treatment (B). Data represents GST activitiy
(sec21) of at least 50 cells per treatment. * indicates significant
difference from the corresponding control at p,0.05. Figure F.
Major metabolic activation pathways of BaP.
(DOCX)
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